Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain Pelthos Therapeutics (NYSE American: PTHS) announced the first patient has been dosed in a placebo-controlled Phase 1b/2a trial of CT2000, an ophthalmic NaV1.7 inhibitor for acute and chronic eye pain. The adaptive study includes ascending-dose Phase 1 and a 28-day Phase 2a MTD period. Results are anticipated by end of 2026. Channel, a Pelthos subsidiary, reported meeting predefined preclinical endpoints for CT2000 in May 2025. The company notes a global chronic ocular pain market estimate of $5.3 billion by 2032.

#PTHS Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

www.stocktitan.net/news/PTHS/pelthos-therap...

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025. 8,948 ZELSUVMI

#PTHS Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/PTHS/pelthos-therap...

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics Horizon Technology Finance Corporation, an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc., with an initial funding of $30 million, and up to $20 million to support future growth. Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI™...

#HRZN #PTHS Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

www.stocktitan.net/news/HRZN/horizon-techno...

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance The minimally dilutive funding will accelerate Pelthos’ highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working

#PTHS Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

www.stocktitan.net/news/PTHS/pelthos-therap...

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice Pelthos Therapeutics (NYSE American: PTHS) acquired Xeglyze (abametapir) from Hatchtech for $1.8 million on Jan 5, 2026.Xeglyze is an FDA-approved prescription topical treatment for head lice in patients 6 months and older (approved July 2020). Pelthos obtained worldwide commercialization rights with no future milestone, royalty, or other payments owed to Hatchtech. The company plans to relaunch Xeglyze in the first half of 2027. The release cites an estimated 6–12 million annual U.S. head-lice infestations among children ages 3–11 as the addressable market context.

#PTHS Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

www.stocktitan.net/news/PTHS/pelthos-therap...

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3% Pelthos Therapeutics (NYSE American: PTHS) signed its first commercial agreement to expand patient access to ZELSUVMI™ (berdazimer) topical gel, 10.3%, an FDA‑approved at‑home treatment for molluscum contagiosum. The company entered a deal via a Group Purchasing Organization with a pharmacy benefit manager that covers more than 20 million lives; formulary inclusion updates began on December 1, 2025. ZELSUVMI launched in July 2025, is approved for patients aged one year and older, and received a Novel Drug designation from FDA in January 2024. Pelthos says the PBM partnership aims to improve coverage, distribution, and patient access to the once‑daily topical gel.

#PTHS Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

www.stocktitan.net/news/PTHS/pelthos-therap...

Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million in net revenues 2,716 ZELSUVMI units prescribed by 1,169 unique prescribers in the third

#PTHS Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results

www.stocktitan.net/news/PTHS/pelthos-therap...

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing Pelthos Therapeutics (NYSE: PTHS) acquired U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1% and closed an $18 million private convertible notes financing on Nov 7, 2025. Pelthos paid $3.0M to Biofrontera and $1.2M to Ferrer upfront, with additional sales‑based milestones and royalties payable. Xepi is FDA‑approved for impetigo in patients two months and older; Pelthos plans a re‑launch in late 2026. The Notes bear 8.5% interest, mature Nov 6, 2027, and convert at an initial price of $34.442. Proceeds will fund the Xepi relaunch, commercial acceleration of ZELSUVMI, and working capital.

#PTHS Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

www.stocktitan.net/news/PTHS/pelthos-therap...

BREAKING NEWS: ( NYSE: #PTHS ) Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum Pelthos Therapeutics (NYSE: PTHS) on Oct 9, 2025 launched the Moms Against Molluscum movement and MomsAgainstMolluscum.com to unite families affected by molluscum contagiosum and share resources.The company highlights its prescription topical ZELSUVMI (berdazimer) 10.3% gel, launched in July 2025 and described as a once-daily, at-home nitric oxide-releasing treatment. ZELSUVMI received a Novel Drug designation from the FDA in Jan 2024. The release cites disease burden: an estimated 16.7 million Americans affected and up to 6 million new U.S. incidents annually, mostly children.

#PTHS Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum

www.stocktitan.net/news/PTHS/pelthos-therap...

First-Ever At-Home Treatment for Molluscum: Pelthos Launches ZELSUVMI Amid $50.1M Strategic Investment Pelthos Therapeutics launches ZELSUVMI, first FDA-approved at-home treatment for molluscum contagiosum. Completes Channel merger, $50.1M financing, and builds 50-person sales force for commercial rollout.

#PTHS Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

www.stocktitan.net/news/PTHS/pelthos-therap...

FDA Breakthrough: New At-Home Gel Shows 33% Success Rate Against Molluscum Skin Infection Revolutionary once-daily gel treatment enables at-home care for millions with molluscum contagiosum. See clinical trial results and how this first FDA-approved option works.

#PTHS #CHRO Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

www.stocktitan.net/news/PTHS/pelthos-therap...

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement Pelthos Therapeutics (NYSE:PTHS) has completed its merger with Channel Therapeutics and secured a $50.1 million private placement. The combined company will begin trading on the NYSE American exchange under the ticker PTHS on July 2, 2025.The private placement, led by Murchinson Ltd., includes the cancellation of $18.8 million in bridge capital. Pelthos will focus on launching ZELSUVMI™, an FDA-designated novel drug for molluscum contagiosum infections, which affects approximately 16.7 million people in the United States. The medication is the first prescription treatment that can be administered at home.The company will also evaluate NaV 1.7 development programs for various pain treatments. Scott Plesha will serve as CEO, while former Channel Therapeutics CEO Frank Knuettel II becomes CFO of the combined entity.

#CHRO #PTHS Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

www.stocktitan.net/news/CHRO/pelthos-therap...